Venturi Wealth Management LLC Boosts Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Venturi Wealth Management LLC increased its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 58.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,373 shares of the company’s stock after purchasing an additional 504 shares during the quarter. Venturi Wealth Management LLC’s holdings in TransMedics Group were worth $86,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Clear Creek Financial Management LLC purchased a new stake in TransMedics Group during the 4th quarter worth approximately $352,000. Vaughan Nelson Investment Management L.P. boosted its stake in TransMedics Group by 9.9% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock valued at $22,547,000 after acquiring an additional 32,605 shares during the period. Baillie Gifford & Co. grew its holdings in shares of TransMedics Group by 14.9% during the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock valued at $16,824,000 after purchasing an additional 34,947 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in shares of TransMedics Group during the 3rd quarter worth approximately $2,560,000. Finally, Charles Schwab Investment Management Inc. boosted its position in TransMedics Group by 2.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after purchasing an additional 6,634 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

Shares of TMDX opened at $71.95 on Monday. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The firm’s 50 day moving average is $66.63 and its 200-day moving average is $104.16. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The stock has a market capitalization of $2.41 billion, a P/E ratio of 76.54 and a beta of 2.12.

Insider Buying and Selling at TransMedics Group

In related news, insider Tamer I. Khayal sold 1,084 shares of TransMedics Group stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at $1,800,835.20. The trade was a 4.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 7.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on TMDX. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Oppenheimer reissued an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Robert W. Baird decreased their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Piper Sandler cut their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Finally, TD Cowen decreased their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.